Omnitek Engineering Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Omnitek Engineering Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.45M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.02M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.06M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $1.07M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.10M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $876.0K | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | $964.4K | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.29M | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $1.07M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.31M | Mar 30, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.06M | Mar 30, 2018 |
| FY2017 | Dec 31, 2016 | $1.30M | Mar 30, 2018 |
| FY2016 | Dec 31, 2015 | $1.74M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $1.44M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $986.6K | Mar 31, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $552.5K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $457.9K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $410.7K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $421.4K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $475.8K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $287.1K | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | $167.5K | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | $500.8K | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $169.1K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $532.1K | Mar 30, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $273.6K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($167.1K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($215.4K) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($196.7K) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $17.4K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($489.7K) | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | ($720.4K) | Apr 1, 2021 |
| FY2018 | Dec 31, 2018 | ($468.4K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2017 | ($1.04M) | Mar 30, 2018 |
| FY2016 | Dec 31, 2016 | ($901.4K) | Mar 31, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($85.9K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($148.5K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($196.1K) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($174.4K) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($189.5K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($467.2K) | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | ($699.6K) | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | ($425.2K) | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | ($1.03M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($900.0K) | Mar 30, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.4K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $70.3K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $67.6K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $66.4K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $63.8K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $82.1K | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | $106.9K | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | $106.9K | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $118.9K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $187.1K | Mar 30, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($244.3K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $30.1K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $17.2K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $9.2K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($130.1K) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($247.5K) | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | ($83.8K) | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | ($103.5K) | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | ($24.5K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($188.1K) | Mar 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.4K | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $14.5K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 7, 2022 |
| FY2019 | Dec 31, 2019 | $0 | Apr 23, 2020 |
| FY2019 | Dec 31, 2018 | $2.7K | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 1, 2019 |
| FY2015 | Dec 31, 2014 | $1.5K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $123.8K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $4.6K | Nov 12, 2014 |
| FY2012 | Dec 31, 2011 | $15.5K | Mar 18, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $754.4K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.12M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $847.2K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $1.11M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.43M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $976.8K | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | $1.11M | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.45M | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $1.63M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.03M | Mar 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.82M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $2.46M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $2.03M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $2.10M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $2.23M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.85M | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | $1.55M | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.35M | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $1.15M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $745.5K | Mar 30, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.07M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($1.35M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($1.19M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | ($986.1K) | Apr 16, 2025 |
| FY2023 | Dec 31, 2021 | ($807.7K) | Apr 16, 2024 |
| FY2021 | Dec 31, 2020 | ($874.1K) | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | ($430.9K) | Apr 1, 2021 |
| FY2020 | Dec 31, 2018 | $94.8K | Apr 1, 2021 |
| FY2019 | Dec 31, 2017 | $476.7K | Apr 23, 2020 |
| FY2018 | Dec 31, 2016 | $1.28M | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.75M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($22.03M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($21.86M) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($21.64M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($21.45M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($21.47M) | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | ($20.98M) | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | ($20.26M) | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | ($19.79M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($18.75M) | Mar 30, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $59.7K | Apr 7, 2022 |
| FY2021 | Dec 31, 2020 | $60.7K | Apr 7, 2022 |
| FY2021 | Dec 31, 2019 | $20.2K | Apr 7, 2022 |
| FY2013 | Dec 31, 2013 | $1.06M | Nov 12, 2014 |
| FY2013 | Dec 31, 2012 | $3.19M | Nov 12, 2014 |
| FY2013 | Dec 31, 2011 | $31.2K | Nov 12, 2014 |
| FY2012 | Dec 31, 2010 | $34.9K | Mar 18, 2013 |
| FY2011 | Dec 31, 2009 | $79.0K | Mar 27, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | 0 | Mar 18, 2013 |
| FY2011 | Dec 31, 2011 | 0 | Mar 27, 2012 |
| FY2011 | Dec 31, 2010 | 0 | Mar 27, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21.95M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 21.95M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 21.95M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | 21.95M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 21.95M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 21.60M | Apr 7, 2022 |
| FY2020 | Dec 31, 2019 | 21.34M | Apr 1, 2021 |
| FY2019 | Dec 31, 2018 | 20.42M | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | 20.28M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 19.98M | Mar 30, 2018 |